Is Stemline Therapeutics Inc (STML) a Good Stock to Buy?

Page 2 of 2

As industrywide interest jumped, key hedge funds have been driving this bullishness. Columbus Circle Investors assembled the most outsized position in Stemline Therapeutics Inc (NASDAQ:STML). Sabby Capital also made a $1.1 million investment in the stock during the quarter. The other fund with new positions in the stock is Gavin Saitowitz and Cisco J. del Valle’s Springbok Capital.

Let’s check out hedge fund activity in other stocks similar to Stemline Therapeutics Inc (NASDAQ:STML). These stocks are Medgenics Inc (NYSEMKT:MDGN), Evolution Petroleum Corporation (NYSEAMEX:EPM), Newtek Business Services, Inc (NASDAQ:NEWT), and West Marine, Inc. (NASDAQ:WMAR). This group of stocks’ market values are closest to STML’s market value.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
MDGN 9 51090 -1
EPM 6 10923 3
NEWT 6 7903 0
WMAR 9 28869 3

As you can see these stocks had an average of 8 hedge funds with bullish positions and the average amount invested in these stocks was $25 million. That figure was $11 million in STML’s case. Medgenics Inc (NYSEMKT:MDGN) is the most popular stock in this table. On the other hand Evolution Petroleum Corporation (NYSEAMEX:EPM) is the least popular one with only 6 bullish hedge fund positions. Compared to these stocks Stemline Therapeutics Inc (NASDAQ:STML) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None

Page 2 of 2